started · updated
GLP-1 medication discontinuation linked to increased health risks
A study published in The Lancet Regional Health – Europe suggests that discontinuing GLP-1 receptor agonists may lead to significant health risks for individuals with type 2 diabetes. An international research team, led by Antonio Ceriello from the Italian institute IRCCS MultiMedica, analyzed health data from over 80,000 patients.
The findings indicate an increased incidence of heart attacks, strokes, and deaths following the cessation of these medications. Researchers noted that changes in weight and blood sugar levels after stopping the treatment do not fully explain these heightened risks. While GLP-1 receptor agonists are known to lower blood sugar and reduce body weight, they also provide cardiovascular protection.
Entities
Antonio Ceriello · Central Association of German Bakers · Federal Ministry of Labour and Social Affairs · Germany · IRCCS MultiMedica · Nichola Ludlam-Raine · Roland Ermer · The Lancet Regional Health – Europe
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 2 SOURCES] The study analyzed health data from more than 80,000 diabetes patients. www.merkur.de
- [● 2 SOURCES] Discontinuing GLP-1 medications is linked to increased risks of heart attack, stroke, and death in type 2 diabetes patients. www.merkur.de
- [● 2 SOURCES] Antonio Ceriello from the Italian research institute IRCCS MultiMedica led the research team. www.merkur.de
- [● 2 SOURCES] Changes in weight and blood sugar after stopping the medication do not fully explain the increased risks. www.merkur.de